Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialMichele Maio, Bohuslav Melichar, Mario Mandalà et al.|The Lancet Oncology|2018Cited by 216
STATISTICAL AND METHODOLOGICAL ISSUES IN EVALUATION OF INTEGRATED CARE PROGRAMSChenglin Ye|MacSphere (McMaster University)|2014Cited by 0